LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・Stryker Corp

Stryker Corp

Slēgts

SektorsVeselības aprūpe

300.74 1.73

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

295.06

Max

305.82

Galvenie mērījumi
By Trading Economics
Ienākumi	-104M 745M
Pārdošana	-1.2B 6B
P/E Sektora vidējais	34.62 49.888
EPS	2.6
Dividenžu ienesīgums	1.13
Peļņas marža	12.375
Darbinieki	56,000
EBITDA	-478M 1.2B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+31.53% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	1.13% 2.38%
Nākamie ieņēmumi	2026. g. 30. jūl.
Nākamais dividenžu datums	2026. g. 31. jūl.
Nākamais Ex dividenžu datums	2026. g. 30. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11B 115B
Iepriekšējā atvēršanas cena	299.01
Iepriekšējā slēgšanas cena	300.74

Ziņu noskaņojums

By Acuity

55%

45%

274 / 344 Rangs Healthcare

Stryker Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 20:41 UTC

Peļņas

Stryker 1Q Sales, Profit Rise as it Dealt with Cyberattack

2026. g. 12. marts 21:42 UTC

Galvenie ziņu notikumi

Stryker Says Cyberattack Disruption Is Continuing

2026. g. 11. marts 19:18 UTC

Galvenie tirgus virzītāji

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026. g. 29. janv. 22:05 UTC

Peļņas

Stryker Logs Higher 4Q Profit On Sales Gains

2025. g. 30. okt. 20:36 UTC

Peļņas

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

2026. g. 30. apr. 20:06 UTC

Peļņas

Stryker 1Q Organic Net Sales Up 2.4%

2026. g. 30. apr. 20:06 UTC

Peļņas

Stryker Backs FY26 Adj EPS $14.90-Adj EPS $15.10 >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker Still Sees FY26 Organic Sales Grwoth 8% to 9.5%

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Adj EPS $2.60 >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q EPS $1.93 >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Net $745M >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Sales $6.02B >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Net $745M >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Adj EPS $2.60 >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q EPS $1.93 >SYK

2026. g. 30. apr. 20:05 UTC

Peļņas

Stryker 1Q Sales $6B >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 16. marts 00:00 UTC

Galvenie ziņu notikumi

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

2026. g. 30. janv. 17:03 UTC

Tirgus saruna

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

2026. g. 29. janv. 21:07 UTC

Peļņas

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

2026. g. 29. janv. 21:05 UTC

Peļņas

Stryker 4Q Adj EPS $4.47 >SYK

2025. g. 5. nov. 19:38 UTC

Peļņas

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

2025. g. 5. nov. 17:00 UTC

Peļņas

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

2025. g. 30. okt. 20:21 UTC

Peļņas

Stryker Lifts FY Sales View After 3Q Revenue Rises

2025. g. 30. okt. 20:05 UTC

Peļņas

Stryker 3Q Adj EPS $3.19 >SYK

2025. g. 30. okt. 20:05 UTC

Peļņas

Stryker 3Q EPS $2.22 >SYK

2025. g. 30. okt. 20:05 UTC

Peļņas

Stryker 3Q Sales $6.1B >SYK

2025. g. 30. okt. 20:05 UTC

Peļņas

Stryker 3Q Net $859M >SYK

Salīdzinājums

Cenas izmaiņa

Stryker Corp Prognoze

Cenas mērķis

By TipRanks

31.53% augšup

Prognoze 12 mēnešiem

Vidējais 388 USD 31.53%

Augstākais 450 USD

Zemākais 315 USD

Pamatojoties uz 22 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Stryker Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

22 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 22 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Stryker Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

274 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.